GLP-1s tied to fewer fragility fractures in type 2 diabetes

Clinical takeaway: For patients with type 2 diabetes considering a GLP-1, these data on bone effects are reassuring. The older assumption of a neutral skeletal effect may be worth revisiting.

Rapid weight loss tends to weaken bone, and GLP-1s drive some of the largest weight loss in medicine. So, the expectation has been these drugs might lead to more fractures, not fewer. But a large new analysis points the other way. Among adults with type 2 diabetes, starting a GLP-1 was tied to lower fragility fracture risk than starting a DPP-4i, and the benefit did not track with how much weight patients lost.

Hip fractures alone carry a one-year mortality of roughly 12% to 36%, and adults with type 2 diabetes already experience bone fracture more despite higher bone density. With about one in four adults with diabetes now having used a GLP-1, even a small shift in fracture risk would be meaningful across such a large population. This study set out to separate any skeletal effect from the weight and glucose changes these drugs are known for.

Over 3 years, GLP-1 users had a 21% lower fragility fracture risk than DPP-4i users. The largest reductions were with vertebral, hip or femur fractures, with no significant change at the distal radius or proximal humerus. The effect diverged by diabetes status: protection held in type 2 diabetes but reversed without it. Benefit was clearest in years 1 and 2 and faded by year 3.

The authors propose that GLP-1s help bone most where metabolic stress and inflammation have already degraded it, as in type 2 diabetes, by supporting bone-building cells and tamping down the signals that drive bone breakdown. Without diabetes, that upside may be absent, leaving only weight-loss-related bone loss, which could explain why fracture risk rose in that group.

The analysis emulated a trial using TriNetX records, matching about 66,800 adults with type 2 diabetes who started a GLP-1 to DPP-4i initiators on 40 baseline factors, followed up to three years. The non-diabetes comparison was weaker, pitting GLP-1 users against never-users. And by the study's own robustness check, only a modest unmeasured difference between groups would be enough to erase the effect.

"These findings suggest that GLP-1 RAs may reduce fragility fracture risk through mechanisms independent of weight loss and glycemic control, highlighting the need for prospective studies to establish causality and define long-term skeletal effects," the authors conclude.

Source: Hamad CD, et al. JAMA Netw Open. 2026 Jul 24. Glucagon-like peptide-1 receptor agonists and fragility fracture risk in type 2 diabetes